Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer

Summary

The purpose of this phase 2 research study is to determine whether a combination of chemotherapy drugs plus radiation therapy, given before surgery in resectable pancreactic cancer, can help to increase the chances of surgeons achieving and R0 resection. The chemotherapy drugs used are gemcitabine and nab-paclitaxel. These drugs are both approved by the FDA for use in treating adults with pancreatic adenocarcinoma. The investigational portion of this study is providing the chemotherapy drugs and radiation therapy before surgery. Primary Endpoint, R) resection rate ≥70%. Secondary Endpoints, Disease free survival, Overall survival , Perioperative mortality and morbidity.

Eligibility

Inclusion Criteria (all criteria must apply):

* Cytologic or histologic proof of adenocarcinoma of the pancreas.
* Localized, potentially resectable tumors.
* Greater or equal to 18 years of age.
* ECOG performance status of 0 or 1.
* Adequate hematologic, renal and hepatic function as defined by:
* ANC greater or equal to 1,500 cells/mm3
* Platelets greater or equal to 100,000 cells/mm3
* Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)
* Serum creatinine ≤ 2 x ULN • ALT ≤ 5 x ULN
* AST ≤ 5 x ULN
* No history of prior therapy for pancreatic cancer.
* No history of active infection requiring IV antibiotics at the start of study treatment
* Non-pregnant and non-breast-feeding.

Exclusion Criteria:

* Patient has borderline resectable or metastatic disease.
* History of malignancy in the last 5 years other than in situ cancer or basal or squamous cell skin cancer or malignancies cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least 5 years.
* Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.

Conditions3

Interventions2

Locations1 site

Find trials near these locations

Related trials

• Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients — National Cancer Institute, Naples
• A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer — BioNTech SE
• A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors — CStone Pharmaceuticals
• A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy. — Jinghui Wang
• A Study for the Adjuvant Treatment of Breast Cancer — Second Affiliated Hospital, School of Medicine, Zhejiang University
• A Study for the Neoadjuvant Treatment of Breast Cancer — Second Affiliated Hospital, School of Medicine, Zhejiang University
• A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer — Akeso
• A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma — Renmin Hospital of Wuhan University

Browse More Trials